Loaded up on Monday’s sale and am waiting to swing some of the higher priced shares to average down and take some profit. I recently learned this is a pretty shorted stock with lots of puts? Still learning about those terms. The ~$10 price fluctuations make more sense to me now! Not complaining since I’m now swing trading this stock for the third time 😅. This is ultimately a long-term position for me and the shorts don’t scare me. This is currently my favorite stock.
Just some thoughts: I recently read an article from last September covering the HBV studies by JNJ/ARWR and VIR. It was mentioned that competing with drug makers could be a factor in profitability. Well, I’m glad VIR announced their collaboration with Gilead, the world’s leader in HBV drugs, in January. Now some ask, Why would Gilead want to eliminate the need for their drugs? Vir is exploring the use of Gilead’s Vemlidy in their functional cure. Its patent expires 2032. Various US studies are in Phase 2 (Europe’s TherVacB is going into Phase 1, I believe). Any FDA approval looks to be about in about 5 years. I’m speculating that Gilead mind as well use the last years of their patent as part of a cure.
With that said, I’m still researching JNJ/ARWR and seeing what other projects they’re up to.
Bullish
W
CEO coming on CNBC today in few hours
j
Good need
Bullish
S
107.77 soon
D
GSK injecting $$$ into $VIR programs
R
what happened to price today did I miss some news
A
Is short squeeze imminent? Could pop to 200!
A
The recent HBV data is nothing short of a miracle. Clearing 94.9 % of the antigen in 8 days with just 6mg. This is by far the most promising result for any drug targeting this virus. The technology will also probably have application for other indications.
S
Will this pop and drop? This is not healthy for people like me who are not day trading. What is the right value for VIR now? Makes it hard to judge.
R
I see it time and time again. A stock is up huge (50%, 100%, etc.) and unsophisticated retail investors still buy at those levels. Never ever buy at those levels. Always wait a day or two for the inevitable pullback.
All my babies doing well today :-) $NVAX, $INO, $VIR, $EVFM
C
Eod will be 75, tmrw will be 60
Bearish
k
What Vir has been working on , DVAX already achieved and trades $11 a shares. I have been following VIr since $16 a shares. After seeing DVAX, I think DVAX should trade $75 a shares not VIR That’s my honest research opinion Good luck
m
sell the news now, it is going to correct hard. 2 up days is lots... watch the profit takers jump in
A
Vir has 4 new products testing or to start testing for COVID treatment and or prophylaxis. Also a hepatitis B treatment. I'm going long on this one . May reach 100 by 2022.
Bullish
Y
Vir Biotechnology is up 12.01% to 49.72
D
Amazing run today ... Vir and Beyond meat ... banner day for this guy
M
We will see well over $100 by end of week, data release and short squeeze, could push this closer to $200, I am buying and buying and buying.
Bullish
k
Tried to short 500 shares but none was available, it means all the hype is short covering that is all
k
I was about to jump in around $65 but when I looked at the insiders transaction and all the selling got me backing off . As of just last week they were selling around $28 . I believe it could be shorts covering their positions
Just some thoughts: I recently read an article from last September covering the HBV studies by JNJ/ARWR and VIR. It was mentioned that competing with drug makers could be a factor in profitability. Well, I’m glad VIR announced their collaboration with Gilead, the world’s leader in HBV drugs, in January. Now some ask, Why would Gilead want to eliminate the need for their drugs? Vir is exploring the use of Gilead’s Vemlidy in their functional cure. Its patent expires 2032. Various US studies are in Phase 2 (Europe’s TherVacB is going into Phase 1, I believe). Any FDA approval looks to be about in about 5 years. I’m speculating that Gilead mind as well use the last years of their patent as part of a cure.
With that said, I’m still researching JNJ/ARWR and seeing what other projects they’re up to.
I have been following VIr since $16 a shares. After seeing DVAX, I think DVAX should trade $75 a shares not VIR
That’s my honest research opinion
Good luck